Axxess Pharma, Inc. Reports Health Canada Approves 11 Prescription and Non-Prescription Drugs
August 09 2010 - 7:00AM
Marketwired
Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company
specializing in the marketing and distribution of both prescription
and non-prescription medical products, is pleased to announce
Health Canada approved 11 of their prescription and
non-prescription drugs. All of these drugs are now being sold in
Canada and have been submitted to Latin America for approval and
distribution throughout their continent. Management anticipates
annual sales from their recently approved drugs to exceed $6
million.
The current list of drugs which have been approved by Health
Canada include:
- Triferrex 150 which is a non-constipating iron supplement for
men and women
- Triferrex Pre-Natal (PN) which is a non-constipating
multi-vitamin to be used prior to, during and after pregnancy (post
partum)
- Gravagol, used for the treatment of migraine headaches
- Monurol, used as a onetime treatment for urinary tract
infections in women
- Urasol, a non-antibiotic for long-term treatment of urinary
tract infections
- Somonol, used as a hypnotic
- Soropon, used exclusively in the treatment of cradle cap in
infants
- Vivol, used as tranquilizer to relieve stress and tension
- Kemsol, used to help treat scleroderma which is a skin
disease
- Hydraxx 1 percent (fragrance), used by dermatologists for very
dry skin
- Hydraxx 2 percent (non-fragrance), used by dermatologists for
very dry skin
"This is an exciting time for our company. We continue to
introduce effective, new, high demand prescription and
non-prescription drugs into the market. Our 11 Health Canada
approved drugs are anticipated to generate over $6 million in
annual sales. All of these products are sold under the Axxess
Pharma brand name," stated Gerald Sequeira, President/CEO. "We look
forward to receiving approval on 11 additional drugs within the
next 3 months."
For more information, please contact Investor Relations at (973)
351-3868.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that
focuses on the marketing of dermatological, therapeutic
nutritionals, pain management and diagnostic products in Canada and
abroad since 1997. Axxess owns 22 established pharmaceutical
prescription products that have proven sales in Canada and
internationally. The company has an experienced management team and
field sales force to market products nationally to hospitals and
retail pharmacies as well as specialized practice areas including
Dermatology and Nephrology,Neurology and Urology.
Safe Harbor
Statements about the Company's future expectations and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby. The above information contains information relating to the
Company that is based on the beliefs of the Company and/or its
management, as well as assumptions made by any information
currently available to the Company or its management. When used in
this document, the words "anticipate," "estimate," "expect,"
"intend," "plans," "projects," and similar expressions, as they
relate to the Company or its management, are intended to identify
forward-looking statements. Such statements reflect the current
view of the Company regarding future events and are subject to
certain risks, uncertainties and assumptions, including the risks
and uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, expected,
intended or projected. In each instance, forward-looking
information should be considered in light of the accompanying
meaningful cautionary statements herein. Factors that could cause
results to differ include, but are not limited to, successful
performance of internal plans, the impact of competitive services
and pricing and general economic risks and uncertainties.
Contact: Taylor Capitol, Inc. Investor Relations Stephen Taylor
973-351-3868 Info@TheStockAlerts.com www.TheStockAlerts.com
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jul 2023 to Jul 2024